Study Group: IBS Gastroenterologists (US)(?)

1) telaprevir appears to improve therapy in hard to treat genotype one. 2)previous treatment failures have a reason to now be retreated. 3)naive treatment patients have better chance for cure with the possibility of only 6 month rather than 12 moths of therapy

Traveller's diarrhea can be a formidable problem particularly in susceptible(eg older) patients. The invasive E Coli is particularly virulent.

Until there is general acceptance of electronic medical records by the majority of independent providers, EHR will have a limited role outside of the large institutional setting. Current software packages are either to complicated and expensive for smaller practices AND lack functionality that these...

Technique mimics the Nissen fundoplication which is done surgically or by laparoscpy. Three months evaluation is useless. For example there is progressive loss of efficacy of Nissen fundoplication over a few years, so that evaluation of this technique will take at least 2-3 years. 

The current treatment for patients with hepatitis C genotype 1 is not optimal. The standard therapy with Peg interferon and ribavirin has an efficacy rate of 48%. The preliminary efficacy data of the combination therapy by adding telaprivir to peg interferone and ribavirin is outstanding at 88%. Only...